Articles
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
Pragmatic adjustments to trial protocols were seen to be essential during the Covid-19 pandemic to avoid trials being abandoned or delayed. Most changes involved reducing the requirements for travelling to centralised trials centres and reducing the level of reporting requirements.…
Their fingers on the button: why neglecting radiation therapists is no longer an option
The job of a radiation therapist may sound straightforward: deliver the right dose of radiation to the right location. But it’s not. These are complex tasks that involve working with data, high-tech equipment and patients. Moreover, by doing each task…
Delivering cancer care during the pandemic: lessons from the ‘first wave’
“My partner had to be admitted to hospital with neutropenia earlier on in her treatment cycle, and she and I are constantly discussing what to do: whether we should ask about suspending treatment, how the risk/benefit equation adds up, whether…
Smoke without fire? Should cancer of unknown primary be treated as a separate disease?
Metastases, but no primary tumour – the diagnosis ‘cancer of unknown primary’ still presents great challenges, even in this age of precision oncology. Cancer of unknown primary (CUP) is an entity that encompasses a heterogenous group of metastatic cancers without…
Raed Al Dieri: Taking pathology from bit part to key player on the European oncology scene
The man steering the organisation dubbed “the leading force in European pathology” is not one to dwell on the negative. Raed Al Dieri, Director General of the European Society of Pathology (ESP), is an internationalist but also a proud Syrian.…
Could covid-19 boost interest in drug repurposing in oncology?
Could the frantic search for drugs to treat patients severely affected by the covid-19 virus be a shot in the arm for new cancer treatments? There have been many headlines about repurposed agents, such as the highly debated antimalarial drug…
Will artificial intelligence revolutionise cancer therapeutics and care?
The first machine learning application in healthcare was approved by the FDA as recently as 2019 to analyse MRI images of the heart. In oncology, applications that make use of artificial intelligence (AI) are appearing thick and fast, from improving…
Prognostic biomarkers: could they help doctors, patients and families to better navigate the end of life?
“We had to explain that the reason she had broken her hip was because she was getting weaker and essentially dying… At that stage knowing whether Mum had days or months left would have been an important factor.” Helen Waddell,…
Rare cancer care: Are European Reference Networks delivering on the promise?
What value can collaboration between EU member states add to the quality of care accessible to all EU citizens? It’s a question that has become urgent and topical with the coronavirus pandemic, and one that EU4Health, the EU’s new funding…
On a mission to beat cancer
One small step for man, one giant leap for mankind – the words Neil Armstrong pronounced as he completed humankind’s first mission to the moon, will – if the European Commission gets its way – soon be pronounced for other…